Project Grant R21DA059754
- The National Institute on Drug Abuse (NIDA) awarded a $109,076 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Illinois on January 25, 2026. The grant will fund a research project to examine the impact of ovarian hormone mechanisms on acute risk for problematic cannabis use in females, particularly during periods of hormonal fluctuation across the menstrual cycle. The project will leverage a novel computational modeling approach to analyze...
- This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on the impact of oral THC consumption during adolescence on the adult mouse brain. The $716,455 award, effective July 1, 2025 through March 31, 2030, will enable researchers at the University of Washington to: Determine how long-term adolescent use of THC-gelatin, alone or in combination with cannabidiol (CBD), impacts...
- This $232,625 project grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to assess the potential of pregnenolone, a signaling specific negative allosteric modulator (NAM) of the CB1 cannabinoid receptor, to reverse symptoms of cannabis intoxication in humans. The study will utilize a within-subjects, double-blind, placebo-controlled design to evaluate the ability of two different doses of pregnenolone (250 mg and...
- The National Institute on Aging (NIA) awarded a 2-year, $405,401 Project Grant under the Aging Research program (CFDA 93.866) to the University of Florida to conduct a multi-level analysis of factors influencing the response to medical marijuana treatment for chronic musculoskeletal pain in older adults. The key objectives are to: 1) Identify gene expression modules associated with changes in chronic pain severity following medical marijuana use, 2) Detect associations between changes in chronic...
- This Project Grant award of $761,367, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to determine whether biomarkers in fetal central nervous system-derived extracellular vesicles can predict derangements in fetal neurodevelopment in women using cannabinoids during pregnancy. The 5-year project, which began on September 1, 2025, will partner with an ongoing NIH-funded clinical cohort of 450 subjects to identify novel...
- This $507,000.00 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the Icahn School of Medicine at Mount Sinai to investigate the epigenetic mechanisms underlying cannabis use disorder. The project, running from September 1, 2025 to May 31, 2030, aims to leverage a translational animal model of voluntary THC consumption to study sex differences and individual variability in...
- This Project Grant award of $220,340 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research at Washington State University to investigate the role of microglia, a type of immune cell in the brain, as a mechanism underlying the cognitive deficits associated with adolescent cannabis use. The study aims to determine if microglial activation is necessary for the impairments in cognitive flexibility observed in adulthood...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Cambridge Public Health Commission, doing business as the Cambridge Health Alliance, will provide $177,110 to study the impact of cannabis legalization and commercialization on substance use and mental health outcomes among individuals with psychosis. The research will utilize quasi-experimental difference-in-difference methods to analyze data from the Population...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $249,108 to Brown University to conduct a multimodal study examining the relationship between cannabis use, trauma, and self-regulatory cognitive processes in emerging adults aged 18-25. The study leverages methodology from a parent NIDA-funded project (R01DA054116) to recruit 70 participants and implement additional self-report and behavioral task...
MOOD, COGNITIVE, AND METABOLIC CONSEQUENCES OF CHRONIC VAPORIZED CANNABIS EXPOSURE IN MOUSE MODELS OF MENOPAUSE - PROJECT SUMMARY THE LEGALIZATION OF RECREATIONAL AND MEDICINAL CANNABIS IN SEVERAL STATES ACROSS THE US HAS INCREASED THE NEED TO BETTER UNDERSTAND ITS EFFECTS ON THE BODY, BRAIN, AND BEHAVIORS IN DIVERSE POPULATIONS. NOTABLY, PEOPLE 50 AND OVER ARE THE FASTEST GROWING GROUP OF CANNABIS USERS IN THE US. AMONG THIS GROUP ARE WOMEN WHO HAVE UNDERGONE THE TRANSITION TO REPRODUCTIVE SENESCENCE, KNOWN AS MENOPAUSE, WHICH OCCURS AT THE AVERAGE AGE OF 51. MENOPAUSE AND THE ATTENDING DECREASE IN CIRCULATING ESTROGENS IS ASSOCIATED WITH A VARIETY OF SYMPTOMS INCLUDING MOOD, ANXIETY, AND COGNITIVE IMPAIRMENTS AS WELL AS METABOLIC CHANGES THAT ARE LINKED TO POOR HEALTH OUTCOMES. AS AN INCREASING NUMBER OF POST-MENOPAUSAL WOMEN USE CANNABIS, EITHER RECREATIONALLY OR MEDICINALLY TO TREAT MENOPAUSE SYMPTOMS, IT WILL BE IMPORTANT TO EVALUATE THE HEALTH RISKS AND BENEFITS OF CANNABIS USE IN THIS UNIQUE POPULATION. HERE, PRECLINICAL MOUSE MODELS ARE PARTICULARLY VALUABLE, AS THEY PROVIDE PRECISE CONTROL OVER CANNABIS TREATMENT (COMPOSITION, FREQUENCY ETC.) AND ENABLE RESEARCHERS TO DISSOCIATE THE CONTRIBUTION OF AGE AND ENDOCRINE STATUS TO VARIOUS NEURAL, BEHAVIORAL, AND METABOLIC OUTCOMES. TO PRODUCE READILY TRANSLATABLE FINDINGS FROM MICE TO HUMANS, PRECLINICAL MODELS SHOULD CLOSELY RESEMBLE HUMAN PATTERNS OF CANNABIS CONSUMPTION. TO THIS END, ALONG WITH CO-I DR. RYAN MCLAUGHLIN, THE DELEVICH LAB HAS RECENTLY VALIDATED A NOVEL VAPOR INHALATION MODEL OF WHOLE PLANT CANNABIS EXTRACT FOR USE IN MICE. THUS, THE OBJECTIVE OF THIS R21 PROPOSAL IS TO UTILIZE THIS MODEL OF CANNABIS USE TO MODEL THE CONSEQUENCES OF CHRONIC CANNABIS USE IN THE POST-MENOPAUSAL STATE. TO THIS END, IN AIM 1A WE WILL FIRST ESTABLISH THE PHARMACOKINETICS OF VAPORIZED CANNABIS IN YOUNG ADULT (POSTNATAL DAY 90) AND AGED (18 MONTH) FEMALE MICE WHO DIFFER BY ENDOCRINE STATUS (OVARIAN INTACT VS. OVARIECTOMIZED). NEXT, IN AIM 1B WE WILL ASSESS THE EFFECT OF CHRONIC CANNABIS VAPOR EXPOSURE ON ENERGY BALANCE, INCLUDING WEIGHT GAIN, BODY COMPOSITION, FOOD INTAKE, AND HOME CAGE LOCOMOTOR ACTIVITY, IN THESE SAME GROUPS. IN AIM 2A WE WILL EXAMINE HOW CHRONIC CANNABIS VAPOR EXPOSURE INFLUENCES MOOD-RELATED ENDPOINTS AND COGNITIVE FLEXIBILITY IN YOUNG VS. AGED OVX AND OVARIAN INTACT FEMALE MICE. FINALLY, GIVEN THE CO- EXPRESSION OF ESTROGEN RECEPTORS AND ENDOCANNABINOID SYSTEM COMPONENTS WITHIN THE MEDIAL PREFRONTAL CORTEX (MPFC), AND THIS REGION'S FUNCTION IN MOOD REGULATION AND COGNITIVE FLEXIBILITY, IN AIM 2B WE WILL ASSESS THE EFFECT OF CHRONIC CANNABIS VAPOR EXPOSURE ON GLUTAMATERGIC AND GABAERGIC SYNAPTIC TRANSMISSION ONTO LAYER II/III AND V PYRAMIDAL NEURONS WITHIN THE PRELIMBIC SUBREGION OF THE MPFC IN YOUNG VS. AGED OVX AND OVARIAN INTACT MICE. TOGETHER, THESE AIMS EMPLOY A CONCEPTUALLY AND TECHNICALLY INNOVATIVE APPROACH TO STUDY THE BRAIN, BODY, AND BEHAVIORAL EFFECTS OF CHRONIC CANNABIS USE IN A VASTLY UNDERSTUDIED POPULATION. FUNDING THIS R21 PROPOSAL WILL ESTABLISH THE VAPORIZED CANNABIS EXPOSURE MODEL WITHIN A MOUSE MODEL OF MENOPAUSE AND GENERATE NECESSARY PILOT DATA TO SUPPORT FUTURE COLLABORATIVE PROPOSALS TO INVESTIGATE THE IMPACT OF CANNABIS USE ON WOMEN'S HEALTH DURING AGING.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $191.3k | 7/30/25 | ||
| Not listed | $229.5k | 8/1/24 |